Fusix Biotech GmbH

We are a spin-out from the Technical University of Munich, specialising in the clinical and commercial development of a proprietary oncolytic virus platform for cancer immunotherapy. Fusix Biotech GmbH is a Munich based start-up founded in 2022. The management team is comprised of the four visionary founders who bring a wealth of scientific expertise and entrepreneurial spirit to Fusix Biotech. With years of experience in oncolytic virus and cancer research PD Dr. Jennifer Altomonte leads our efforts in driving innovation, advancing research and shaping the future of cancer immunotherapy. Together, our management team is united by a shared commitment to advancing cancer care and making a meaningful difference in the lives of cancer patients worldwide.